115 related articles for article (PubMed ID: 27002766)
1. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Li Z; Lv T; Liu Y; Huang X; Qiu Z; Li J
Cancer Biomark; 2016 Mar; 16(4):633-9. PubMed ID: 27002766
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
3. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.
Zhang K; Chen H; Wu G; Chen K; Yang H
Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803
[TBL] [Abstract][Full Text] [Related]
4. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
5. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.
Chen H; Zhang K; Wu G; Song D; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(11):14741-8. PubMed ID: 26823799
[TBL] [Abstract][Full Text] [Related]
6. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
[TBL] [Abstract][Full Text] [Related]
7. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
8. Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma.
Zou MX; Huang W; Wang XB; Lv GH; Li J; Deng YW
Int J Clin Exp Pathol; 2014; 7(8):4877-85. PubMed ID: 25197358
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients.
Zou MX; Huang W; Wang XB; Li J; Lv GH; Wang B; Deng YW
Eur Spine J; 2015 Aug; 24(8):1738-46. PubMed ID: 25850393
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
Zhai L; Li S; Li H; Zheng Y; Lang R; Fan Y; Gu F; Guo X; Zhang X; Fu L
Int J Clin Exp Pathol; 2015; 8(6):7059-71. PubMed ID: 26261599
[TBL] [Abstract][Full Text] [Related]
12. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
[TBL] [Abstract][Full Text] [Related]
13. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
15. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma.
Zhou M; Chen K; Yang H; Wang G; Lu J; Ji Y; Wu C; Chen C
J Neurooncol; 2014 Jan; 116(1):77-82. PubMed ID: 24135846
[TBL] [Abstract][Full Text] [Related]
16. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W
Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.
He G; Liu X; Pan X; Ma Y; Liu X
Clin Transl Oncol; 2020 Dec; 22(12):2324-2332. PubMed ID: 32504188
[TBL] [Abstract][Full Text] [Related]
18. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
19. SNF5 as a prognostic factor in skull base chordoma.
Li M; Zhai Y; Bai J; Wang S; Gao H; Li C; Gui S; Du J; Zhang Y
J Neurooncol; 2018 Mar; 137(1):139-146. PubMed ID: 29222701
[TBL] [Abstract][Full Text] [Related]
20. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
